CT
ABBV icon

Colonial Trust’s AbbVie ABBV Stock Holding History

Colonial Trust’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.08M Sell
9,566
-98
-1% -$21.7K 0.28% 88
2025
Q4 		$2.21M Buy
9,664
+359
+4% +$81.8K 0.29% 83
2025
Q3 		$2.15M Sell
9,305
-196
-2% -$39.9K 0.29% 84
2025
Q2 		$1.76M Buy
9,501
+103
+1% +$19.1K 0.26% 90
2025
Q1 		$1.97M Buy
9,398
+12
+0.1% +$2.33K 0.31% 81
2024
Q4 		$1.67M Sell
9,386
-2,701
-22% -$497K 0.25% 89
2024
Q3 		$2.39M Buy
12,087
+2,695
+29% +$503K 0.37% 72
2024
Q2 		$1.61M Buy
9,392
+475
+5% +$78.7K 0.28% 82
2024
Q1 		$1.62M Sell
8,917
-52
-0.6% -$8.96K 0.3% 80
2023
Q4 		$1.39M Buy
8,969
+272
+3% +$39.7K 0.29% 84
2023
Q3 		$1.3M Buy
8,697
+78
+0.9% +$11.5K 0.32% 75
2023
Q2 		$1.16M Buy
8,619
+400
+5% +$58.7K 0.28% 82
2023
Q1 		$1.31M Buy
8,219
+1,127
+16% +$172K 0.33% 77
2022
Q4 		$1.15M Buy
7,092
+244
+4% +$37.4K 0.31% 78
2022
Q3 		$919K Buy
+6,848
New +$983K 0.29% 84

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Colonial Trust's ABBV Position: Q1 2026 in Review

Colonial Trust reduced its AbbVie (ABBV) stake by 1% in Q1 2026, selling an estimated $21.7K and leaving 9,566 shares worth $2.08M. The position accounts for 0.28% of the portfolio, ranked #88.

Colonial Trust first reported a position in ABBV in Q3 2022 and has held it in 15 quarters since. The position peaked at $2.39M in Q3 2024. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Colonial Trust held 9,566 shares of AbbVie worth $2.08M as of Q1 2026.
  • Colonial Trust sold 98 AbbVie shares in Q1 2026, an estimated $21.7K.
  • AbbVie made up 0.28% of Colonial Trust's portfolio in Q1 2026, its #88 holding.
  • Colonial Trust first reported a position in AbbVie in Q3 2022 and has held it in 15 quarters since.
  • Colonial Trust's AbbVie position peaked at $2.39M in Q3 2024.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Colonial Trust's 13F filing for Q1 2026, filed 12 May 2026.